Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study will assess the effect of gluten on gut barrier function. Investigators at the Mayo Clinic have developed a new gut permeability test using rhamnose (sugar & water solution), and are hoping to prove its effectiveness in a clinical setting.
The aim of this study is to assess effect of gluten on the gut barrier function in patients at high risk for celiac disease and non-celiac gluten sensitivity (NCGS) patients. This study will assess the gut permeability in three groups of patients 1) children who are at high risk for developing celiac disease (CD) (siblings of patients with celiac disease), 2) Children who are self-diagnosed with NCGS and 3) control group of patients matched for age and gender. Patients will undergo celiac serologic and genetic testing, after which the rhamnose test will be performed to assess the presence of increased gut permeability.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| High risk group | Children who are at high risk for developing celiac disease (siblings diagnosed with celiac disease). | ||
| Non-celiac group | Children who are self-diagnosed with non-celiac gluten sensitivity. | ||
| Control Group | Healthy control group (matched for age and gender). |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Gut Permeability | Assess the effect of gluten on gut permeability in children at high risk of developing celiac disease or gluten sensitivity | Baseline |
Not provided
Not provided
High Risk group:
Non-Celiac Gluten Sensitivity group:
Healthy group:
Not provided
Not provided
The study population will consist of three groups of children, aged 2-17 years. The first group will be children with siblings that have celiac disease, the second group will be children with non-celiac gluten sensitivity and the third group will be healthy children.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Imad Absah, MD | Mayo Clinic | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D002446 | Celiac Disease |
| D006967 | Hypersensitivity |
| D005767 | Gastrointestinal Diseases |
| D004066 | Digestive System Diseases |
| ID | Term |
|---|---|
| D008286 | Malabsorption Syndromes |
| D007410 | Intestinal Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| D007154 | Immune System Diseases |